Ultragenyx Pharmaceuticals Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
5/15/2013 9:02:12 AM
More...
|
Ultragenyx Pharmaceuticals Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President
5/1/2013 11:39:45 AM
More...
|
Ultragenyx Pharmaceuticals to Present at the 20th Annual Future Leaders in the Biotech Industry Conference
3/29/2013 10:18:50 AM
More...
|
Ultragenyx Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
3/4/2013 11:20:36 AM
More...
|
Ultragenyx to Present at the 2013 31st Annual J.P. Morgan Healthcare Conference
1/2/2013 9:12:59 AM
More...
|
Ultragenyx, Led by BioMarin Pharmaceutical Inc. (BMRN) Vet, Snags $75 Million for Ultra-Rare Diseases
12/20/2012 7:13:16 AM
More...
|
Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy
10/30/2012 6:52:18 AM
More...
|
Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 17th Annual World Muscle Society Congress
10/11/2012 9:37:57 AM
More...
|
Ultragenyx to Present at the 11th Annual Biotechnology Industry Organization (BIO) Investor Forum in San Francisco
10/3/2012 9:44:54 AM
More...
|
Ultragenyx to Present at the Stifel Nicolaus Weisel Healthcare Conference 2012 in Boston
8/30/2012 9:19:46 AM
More...
|
|